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Summary 
Background:  
The first UK guidelines for the management of hidradenitis suppurativa (HS) were published by 
the British Association of Dermatologists (BAD) in 2018. The guidelines contained a set of audit 
criteria.
Objective: 
To evaluate current HS management against the audit standards in the BAD guidelines.
Methods: 
BAD members were invited to complete audit questionnaires between January and May 2020 for 
five consecutive HS patients per department. 
Results: 
Eighty-eight centres participated, providing data for 406 patients. Disease staging using the 
Hurley system and disease severity using a validated tool during follow-ups were documented in 
75% and 56%. Quality of life (QoL) and pain were documented in 49% and 50%. Screening for 
cardiovascular disease risk factors was as follows: smoking 75%, body mass index (BMI) 27% and 
others such as lipids and diabetes 57%. Screening for depression and anxiety was performed in 
40% and 25%. Support for smokers or obese patients was documented in 35% and 23%. One 
hundred eighty-two patients were on adalimumab, of whom 68% had documentation of baseline 
disease severity, and 76% documented inadequate response or contraindications to systemic 
treatments.  Forty-four percent of patients continued on adalimumab despite having less than 
25% improvement in lesion count. 
Conclusion: 
UK dermatologists performed well against several audit standards, including documenting 
disease staging at baseline and smoking status. However, improvements are needed, particularly 
with regard to screening and management of comorbidities that could reduce the long-term 
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Introduction 
Hidradenitis suppurativa (HS) is a painful chronic suppurative skin condition with a relapsing and 
remitting course that mostly affects the intertriginous areas. The global prevalence of HS is 
around 1% affecting females more commonly than males in Europe and North America with a 
ratio of 3:1, and typically beginning in the second or third decade of life. (1, 2) HS is associated 
with substantial morbidity due to pain and scarring. (3)
In 2018, the British Association of Dermatologists (BAD) published the first UK guidelines for the 
management of HS. (4) The initial management in mild-to-moderate HS includes a topical 
antiseptic and oral tetracyclines. The second-line treatment is a combination of clindamycin and 
rifampicin for 10-12 weeks. When there is an inadequate response, dapsone or acitretin (the 
latter reserved for males and non-fertile females) are the next lines of therapy. In case of 
treatment failure with two or more systemic therapies, or the presence of contraindications, the 
patient may proceed to biologic therapy with weekly adalimumab injections. 
The guidelines have several recommendations for more comprehensive management of people 
with HS and audit criteria were established. All people with HS must be provided with a patient 
information leaflet (PIL) available on the BAD website (www.bad.org.uk/leaflets).  Hurley staging 
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instruments like the DLQI, Pain Numeric Rating Scale (Pain NRS) or Pain Visual Analogue Scale 
(VAS) should be documented at each visit. Additionally, at each clinic visit, smoking status and 
body mass index (BMI) should be assessed.  Counselling and education should be offered to all 
smokers and those with a BMI ≥35 kg/m2. Screening for mental health problems and 
cardiovascular disease (CVD) risk factors should be undertaken annually to identify at-risk 
patients as per guidelines.
When commencing adalimumab, baseline lesion count and Hurley staging must be documented. 
At 12 weeks, an improvement of less than 25% in the lesion count, or an increase in draining 
sinuses or abscesses, should warrant discontinuation of adalimumab. Those undergoing surgery 
need to be aware of the long recovery time postoperatively, and it is necessary that all patients 
have a pre-operative discussion with their clinicians to manage expectations appropriately. 
Our audit aims to assess the current clinical practices in these areas against the audit standards 
set in the guidelines.  
Methodology
We invited all members of the BAD to participate in a national audit between January and May 
2020. Each participant was requested to collect the data from five consecutive people with HS 
per department, covering the work of one or more clinicians, under follow-up in their 
department for a minimum of 12 months. All data were obtained from respondents using a 
Microsoft Excel spreadsheet proforma returned to the BAD by email. No patient-identifiable data 
were requested. Initial data extraction was conducted using a novel and reproducible program 
written in the R statistical language version 3.6 and the readxl package (REF 1). Code and a blank 
example of the questionnaire can be found at https://github.com/sps41/HSaudit (DOI: 
10.5281/zenodo.3885305). Code is freely usable under an MIT license. (5) The data analysis was 
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Results 
We received responses from 82 BAD members covering 88 hospitals across the UK, as shown in 
Figure 1.  In total, data from 406 patients were included in the final data analysis. The results 
showed that 41% of cases had documentation of receiving a PIL. There was documentation of 
Hurley staging at baseline in 75%, and disease severity using a validated tool in  56% of cases. 
QoL and pain were documented in 49% and 50%, respectively (Figure2). 
Smoking status was documented in 75% of cases; 35% of those identified as smokers were 
offered a referral to a smoking cessation service. Almost half had their weight recorded, and 27% 
had their BMI documented. Of those with a BMI ≥35 kg/m2, 23% were referred to a dietician 
(Figure 3). Our data showed that screening for depression and anxiety was documented in  40% 
and 25% of cases, respectively. Screening for risk factors for CVD was recorded in 57% (Figure 4).
Of the 182 patients who were on adalimumab therapy, 77% had documentation of baseline 
lesion count. Documentation of Hurley staging was available in 68%, and any contraindications or 
failure to respond to conventional therapy was noted in 76%. A total of 44% had documentation 
of stopping treatment when there was a reduction of 25% or less in inflammatory nodule and 
abscess lesion count. The data show that approximately one-third (30%) underwent surgical 
intervention, of whom the majority had documentation of pre-surgical discussion (74%).
Discussion 
Our audit revealed there are areas where documentation was done well, in 70% or more, 
covering baseline disease severity, smoking status and baseline documentation prior to starting 
adalimumab therapy. Other areas require improvement, especially in referring smokers and 
those with BMI ≥35 kg/m2 to appropriate services, and screening for anxiety, aspects of holistic 
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In many cases, people with HS spend years before getting a correct diagnosis and being seen by a 
specialist. (6) With the plethora of misinformation about the disease, it is important for those 
with HS to have reliable sources of information to better understand the condition. The results 
show that there was insufficient documentation of the provision of a PIL (41%). Classifying 
patients at baseline into mild, moderate or severe based on the Hurley system assists in triaging 
and management decisions, and it was encouraging that most had documentation of the Hurley 
staging at baseline (75%). The burden of HS on QoL is often substantial and pain is the most 
influential symptom affecting QoL. (7) Assessment of disease severity using validated 
instruments was done in almost half of cases. 
Smokers are twice as likely to develop HS (8), and they may have more severe disease compared 
to non-smokers. (9) Smoking status was documented in most cases but only one-third of those 
requiring smoking cessation support received a referral.  There is as yet no definitive evidence to 
confirm that quitting smoking attenuates disease severity (9); however, non-smokers appear to 
have a better response to medical therapy compared to smokers. (10)
People with HS have an increased risk of developing major adverse cardiovascular events (MACE) 
(Incidence rate ratio (IRR) 1.53) and increased mortality (IRR 1.35). (11) There is a known 
association between HS and metabolic syndrome. (12) These data make a compelling case to 
screen people with HS for risk factors for CVD. In our cohort,  23% with obesity had a  referral to 
weight management services. Screening for diabetes and hyperlipidaemia was performed in 57%. 
HS is a painful disease and has a profound impact on mental health with an increased risk of 
suicide. (13, 14) The guidelines recommend annual screening for mental health disease, and in 
our audit, only 40% and 25% were screened for depression and anxiety, respectively. All these 
factors are interrelated and emphasize the importance of a holistic approach in managing people 
with HS .
In our audit,  46% were on adalimumab. The nodule count and Hurley staging were documented 
in two-thirds of cases. Of note, 44% remained on treatment despite having a suboptimal 
response based on the guideline recommendations. It may be that adjuvant therapy was 
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in the context that other biologic therapy options are difficult to access for HS (and may not be 
funded) in the UK. 
In terms of study limitations, the results of the audit may have been influenced by self-auditing 
which would introduce bias.  Additionally, the audit data may reflect a lack of documentation, 
rather than true practice. 
Our national audit was performed relatively soon after the publication of the first UK guidelines 
for managing people with HS, and the results demonstrate substantial variation in adherence to 
the audit criteria; therefore, this would serve as a baseline performance for future re-audits. 
There are areas such as documenting Hurley staging in which UK dermatologists are performing 
well and there is a need for improvement in several aspects such as screening for CVD risk factors 
and mental health problems. Implementing the guidelines recommendations may be impeded by 
the lack of resources and supporting services in some areas and more recently by the move 
towards virtual consultations during the Covid-19 outbreak. We suggest that clinicians use an HS 
proforma to ensure that the data required are collected routinely at each patient appointment.  
Conclusion 
The BAD HS guidelines were intended to encourage best practice and reduce inequalities in HS 
care across the UK. The audit results show that clinicians are already performing relatively well in 
some areas but improvements are needed, particularly with regard to screening and 
management of comorbidities that could reduce the long-term complications associated with HS. 
As always, a re-audit is needed to determine whether the guidelines and associated audit criteria 
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 Use a standardized data collection form in the clinic and annual proformas to screen CVD 
risk factors, depression and anxiety. 
 Engage with local resources for lifestyle modification (i.e. smoking cessation and weight 
loss).
 Set up HS MDT clinics for local integration between dermatology, HS surgery and wound 
healing services.
 Reaudit in 5 years to evaluate changes in practice. 
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Figure2: Histogram showing the percentage of audited patients for whom there was 
documentation of; (1) baseline disease stage using Hurley system, (2) disease severity using 




















Figure 3: Histogram demonstrating the percentage of audited patients for whom 
documentation was available for; (1) smoking status, (2) referral to smoking cessation 




Figure 4: Histogram showing the percentage of audited patients for whom there was 
documentation of; (1) screening for depression; (2) screening for anxiety; (3) screening for 
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